Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by thenforcer2on Jan 18, 2010 10:18pm
436 Views
Post# 16693060

alert issued-------

alert issued-------NEW YORK, January 18 2010  9.15 pm Analysts at Credit Suisse upgrade United Reef Limited URP.V from "neutral" to "perform." 
On further review, the company is in the process of closing two gold properties and possibility of drilling in the first quarter of 2010.

The shares are a" BUY"  with little downside at this level .
The short to mid term target is .25 CDN...
Bullboard Posts